Literature DB >> 20458452

[Implantation of cardioverter-defibrillators. How much anesthesia is necessary?].

T Sellmann1, M Winterhalter, U Herold, P Kienbaum.   

Abstract

Updated cardiologic guidelines constitute the background for an extended spectrum of indications for the implantation of automatic implantable cardioverter defibrillators (AICDs) and lead to an increasing number of operative implantations of AICDs. Moreover, during implantation of devices for cardiac resynchronization therapy the anesthesiologist is responsible for the most critically ill patients with the longest duration of surgery. As a result anesthesiologists face an increasing number of critically ill patients, whose management contributes to perioperative outcome. Automatic implantable cardioverter defibrillators can be implanted either during general anesthesia, local anesthesia or during a combination of local anesthesia combined with deep conscious sedation accomplished by an anesthesiologist. Besides economic aspects there is an increasing demand for anesthesia with the least cardiovascular side effects and rapid recovery in the often seriously ill patient with preexisting limitations of cardiac and pulmonary functions. Accordingly procedure and anesthesia-associated risks are reviewed and an algorithm for anesthesia management is suggested.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20458452     DOI: 10.1007/s00101-010-1737-3

Source DB:  PubMed          Journal:  Anaesthesist        ISSN: 0003-2417            Impact factor:   1.041


  89 in total

1.  [Guidelines for heart pacemaker therapy].

Authors:  B Lemke; B Nowak; D Pfeiffer
Journal:  Z Kardiol       Date:  2005-10

2.  Principles of thoracic anesthesia.

Authors:  S Tarhan; E A Moffitt
Journal:  Surg Clin North Am       Date:  1973-08       Impact factor: 2.741

Review 3.  Review article: age related alterations in respiratory function - anesthetic considerations.

Authors:  Juraj Sprung; Ognjen Gajic; David O Warner
Journal:  Can J Anaesth       Date:  2006-12       Impact factor: 5.063

4.  Cardiac output is not affected during intraoperative testing of the automatic implantable cardioverter defibrillator.

Authors:  J Meyer; T Möllhoff; T Seifert; J Brunn; J Rötker; M Block; T Prien
Journal:  J Cardiovasc Electrophysiol       Date:  1996-03

5.  Canadian implantable defibrillator study (CIDS) : a randomized trial of the implantable cardioverter defibrillator against amiodarone.

Authors:  S J Connolly; M Gent; R S Roberts; P Dorian; D Roy; R S Sheldon; L B Mitchell; M S Green; G J Klein; B O'Brien
Journal:  Circulation       Date:  2000-03-21       Impact factor: 29.690

6.  Diazepam-fentanyl interaction--hemodynamic and hormonal effects in coronary artery surgery.

Authors:  R C Tomicheck; C E Rosow; D M Philbin; J Moss; R S Teplick; R C Schneider
Journal:  Anesth Analg       Date:  1983-10       Impact factor: 5.108

7.  Opiates increase plasma catecholamines in humans.

Authors:  M Hoehe; T Duka
Journal:  Psychoneuroendocrinology       Date:  1993       Impact factor: 4.905

8.  Differential effects of ketamine isomers on neuronal and extraneuronal catecholamine uptake mechanisms.

Authors:  P M Lundy; P A Lockwood; G Thompson; R Frew
Journal:  Anesthesiology       Date:  1986-03       Impact factor: 7.892

9.  Update on cardiovascular implantable electronic device infections and their management: a scientific statement from the American Heart Association.

Authors:  Larry M Baddour; Andrew E Epstein; Christopher C Erickson; Bradley P Knight; Matthew E Levison; Peter B Lockhart; Frederick A Masoudi; Eric J Okum; Walter R Wilson; Lee B Beerman; Ann F Bolger; N A Mark Estes; Michael Gewitz; Jane W Newburger; Eleanor B Schron; Kathryn A Taubert
Journal:  Circulation       Date:  2010-01-04       Impact factor: 29.690

10.  Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure.

Authors:  W N Leimbach; B G Wallin; R G Victor; P E Aylward; G Sundlöf; A L Mark
Journal:  Circulation       Date:  1986-05       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.